After Zacks Investment Research downgraded Surgery Partners from a hold to a sell, other analysts are following suit, Transcript Daily reports.
Here's what you should know:
1. BidaskClub assigned Surgery Partners a sell rating in its latest research note.
2. Stifel Nicolaus assigned the company a hold rating, but dropped its price objective from $19 a share to $18 a share.
3. On average analysts project a price target of $21.40 for Surgery Partners.
4. Surgery Partners closed Jan. 24 at $21.38.